A Phase 3 interventional study of 0.5% Ivermectin Cream and Placebo control in Head Lice, sponsored by Topaz Pharmaceuticals Inc. Completed at 7 sites in United States. Open to participants aged 5 Months and older. Per ClinicalTrials.gov, last updated 2012-04-06.
Sponsored by Topaz Pharmaceuticals Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.
Topaz Pharmaceuticals Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1
Drug: 0.5% Ivermectin Cream
Up to 4 ounces of topical control applied to hair and scalp on day 1.
Drug: Placebo control
Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
up to 4 ounces of topical vehicle control to head and scalp on day 1.
Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Treatment success, defined as absence of live lice, was assessed in index subjects, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
Time frame: Day 2 up to Day 15 post-application
Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
Time frame: Day 2 up to Day 15 post-application
Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Adverse events were defined and classified as follows: 'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention.
Time frame: Day 2 up to Day 15 post-application
Summary of the Reported Skin/Scalp Irritation Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Severe skin/scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.
Time frame: Day 2 up to Day 15 post-application
Participants were enrolled and treated from 4 March 2010 to 17 June 2010 in 8 US clinical centers.
| Milestone | 0.5% Ivermectin | Vehicle Control |
|---|---|---|
| Started | 169 | 202 |
| Completed | 161 | 198 |
| Not completed | 8 | 4 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Lost to follow-up | 7 | 0 |
| Withdrew: Protocol violation | 0 | 2 |
Treatment success, defined as absence of live lice, was assessed in index subjects, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
| Percent of Participants | 0.5% Ivermectin | Vehicle Control |
|---|---|---|
| Day 15 (LOCF Imputation) | 71 | 19 (0 to 0) |
| Day 15 (Treatment Failure Imputation) | 69 | 18 (0 to 0) |
Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
| Percent of Participants | 0.5% Ivermectin | Vehicle Control |
|---|---|---|
| Day 15 (LOCF Imputation) | 78 | 23 (0 to 0) |
| Day 15 (Treatment Failure Imputation) | 72 | 21 (0 to 0) |
Adverse events were defined and classified as follows: 'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention.
| Participants | 0.5% Ivermectin | Vehicle Control |
|---|---|---|
| Any Conjunctivitis | 1 | 0 (0 to 0) |
| Severe Conjunctivitis | 0 | 0 (0 to 0) |
| Any Ocular Hyperemia | 1 | 1 (0 to 0) |
| Severe Ocular Hyperemia | 0 | 0 (0 to 0) |
| Any Toothache | 1 | 0 (0 to 0) |
| Severe Toothache | 0 | 0 (0 to 0) |
| Any Vomiting | 0 | 1 (0 to 0) |
| Severe Vomiting | 0 | 0 (0 to 0) |
| Any Pyrexia | 0 | 1 (0 to 0) |
| Severe Pyrexia | 0 | 0 (0 to 0) |
| Any Otitis Media | 0 | 1 (0 to 0) |
| Severe Otitis Media | 0 | 0 (0 to 0) |
| Any Excoriation | 1 | 1 (0 to 0) |
| Severe Excoriation | 0 | 0 (0 to 0) |
| Any Injury | 0 | 1 (0 to 0) |
| Severe Injury | 0 | 0 (0 to 0) |
| Any Scratch | 0 | 1 (0 to 0) |
| Severe Scratch | 0 | 0 (0 to 0) |
| Any Musculoskeletal Pain | 0 | 1 (0 to 0) |
| Severe Musculoskeletal Pain | 0 | 0 (0 to 0) |
| Any Pain in Extremity | 0 | 1 (0 to 0) |
| Severe Pain in Extremity | 0 | 0 (0 to 0) |
| Any Cough | 1 | 0 (0 to 0) |
| Severe Cough | 0 | 0 (0 to 0) |
| Any Dandruff | 1 | 0 (0 to 0) |
| Severe Dandruff | 0 | 0 (0 to 0) |
| Any Dry Skin | 1 | 0 (0 to 0) |
| Severe Dry Skin | 0 | 0 (0 to 0) |
| Any Erythema | 2 | 3 (0 to 0) |
| Severe Erythema | 0 | 0 (0 to 0) |
| Any Pruritus | 0 | 2 (0 to 0) |
| Severe Pruritus | 0 | 0 (0 to 0) |
Severe skin/scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.
| Participants | 0.5% Ivermectin | Vehicle Control |
|---|---|---|
| Any Pruritus Day 1 (Pre-treatment; N = 169, 202) | 124 | 147 (0 to 0) |
| Severe Pruritus Day 1 (Pre-treatment; N= 169, 202) | 12 | 8 (0 to 0) |
| Any Pruritus Day 2 (N = 166, 200) | 55 | 104 (0 to 0) |
| Severe Pruritus Day 2 (N = 166, 200) | 1 | 2 (0 to 0) |
| Any Pruritus Day 8 (N = 148, 58) | 19 | 14 (0 to 0) |
| Severe Pruritus Day 8 (N = 148, 58) | 0 | 0 (0 to 0) |
| Any Pruritus Day 15 (N = 142, 53) | 13 | 8 (0 to 0) |
| Severe Pruritus Day 15 (N = 142, 53) | 0 | 0 (0 to 0) |
| Erythema Day 1 (Pre-treatment; N = 169, 202) | 45 | 53 (0 to 0) |
| Severe Erythema Day 1 (Pre-treatment; N= 169, 202) | 0 | 0 (0 to 0) |
| Any Erythema Day 2 (N = 166, 200) | 31 | 41 (0 to 0) |
| Severe Erythema Day 2 (N = 166, 200) | 0 | 0 (0 to 0) |
| Any Erythema Day 8 (N = 148, 58) | 8 | 1 (0 to 0) |
| Severe Erythema Day 8 (N = 148, 58) | 0 | 0 (0 to 0) |
| Any Erythema Day 15 (N = 142, 53) | 4 | 0 (0 to 0) |
| Severe Erythema Day 15 (N = 142, 53) | 0 | 0 (0 to 0) |
| Any Excoriation Day 1 (Pre-treatment; N= 169, 202) | 42 | 46 (0 to 0) |
| Severe Excoriation Day 1 (Pre-treatment N=169, 202 | 0 | 1 (0 to 0) |
| Any Excoriation Day 2 (N = 166, 200) | 36 | 46 (0 to 0) |
| Severe Excoriation Day 2 (N = 166, 200) | 0 | 1 (0 to 0) |
| Any Excoriation Day 8 (N = 148, 58) | 13 | 5 (0 to 0) |
| Severe Excoriation Day 8 (N = 148, 58) | 0 | 0 (0 to 0) |
| Any Excoriation Day 15 (N = 142, 53) | 5 | 4 |
| Severe Excoriation Day 15 (N = 142, 53) | 0 | 0 |
| Any Pyoderma Day 1 (Pre-treatment; N= 169, 202) | 3 | 2 |
| Severe Pyoderma Day 1 (Pre-treatment; N= 169, 202) | 0 | 0 |
| Any Pyoderma Day 2 (N = 166, 200) | 3 | 2 |
| Severe Pyoderma Day 2 (N = 166, 200) | 0 | 0 |
| Any Pyoderma Day 8 (N = 148, 58) | 1 | 1 |
| Severe Pyoderma Day 8 (N = 148, 58) | 0 | 0 |
| Any Pyoderma Day 15 (N = 142, 53) | 2 | 1 |
| Severe Pyoderma Day 15 (N = 142, 53) | 0 | 0 |
Collected over Adverse event data were collected from the day of application (Day 1) through Day 28 post-application.. Non-serious events are listed at a 5.00% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5% Ivermectin | — | 0/169 (0%) | 0/169 (0%) |
| Vehicle Control | — | 0/202 (0%) | 0/202 (0%) |
| Age, Categorical(Participants) | 0.5% Ivermectin | Vehicle Control | Total |
|---|---|---|---|
| <=18 years | 126 | 150 | 276 |
| Between 18 and 65 years | 42 | 52 | 94 |
| >=65 years | 1 | 0 | 1 |
| Age Continuous(Years) | 0.5% Ivermectin | Vehicle Control | Total |
|---|---|---|---|
| Mean | 14.37 ± 13.33 | 15.19 ± 13.85 | 14.82 ± 13.60 |
| Sex: Female, Male(Participants) | 0.5% Ivermectin | Vehicle Control | Total |
|---|---|---|---|
| Female | 136 | 151 | 287 |
| Male | 33 | 51 | 84 |
| Region of Enrollment(Participants) | 0.5% Ivermectin | Vehicle Control | Total |
|---|---|---|---|
| United States | 169 | 202 | 371 |
The record gives a start of Mar 2010, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 10 months after primary completion. A results delay was requested in Mar 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin
Topaz Pharmaceuticals Inc